All Type of News
MOHW, “We are doing our best to improve passing rates and registration periods on new anticancer drugs”
The Ministry of Health and Welfare(MOHW) once again stressed it has put the best effort on improving the passing rate and minimizing the period of drug assessments for the health insurance benefit for new anticancer d...
MOHW, “Tax deductions for biobetters and innovative drugs will soon be legalized”
Soon, measures to deduct taxes on R&Ds for biobetters and innovative drugs is expected to be legalized.
Vice Minister Moon-gyu Bang of Health and Welfare held the ‘2nd Private and Public Council to Foster Bio-Health ...
‘Guzzling OTC Drug Price Research’ in final phase, to be announced by May
The research of guzzling OTC drugs’ selling prices entered the finalizing phase, expected to be announced by May as expected.
The Ministry of Health and Welfare announced the fact-finding research on guzzling OTC dr...
Great war of domestic pharmaceutical distribution approaching
As large distribution companies, such as Geo-Young, Baekje Pharmaceutical and Dongwon Pharmaceutical Wholesale, have started to maximize distribution efficiency and secure new bases, the great war of distribution seem...
Boycott led by pharmacies against Oxy Reckitt Benckiser products spread across the nation
The boycott led by pharmacies against Oxy Reckitt Benckiser products has spread across the nation.
Caused by the Oxy Reckitt Benckiser’s irresponsible responses to the humidifier disinfectant death case, the boycott...
Pfizer’s counterattack against 13 domestic companiesPfizer which successfully protected the ‘Lyrica’ use patent started to counterattack. It has continued lawsuits against domestic companies which launched generics.
Pfizer Phar...
|
SC-type Remsima starts to aim for TNF-α inhibitor market
Celltrion started to conduct a clinical trial of the SC-type of Remsima, an autoimmune treatment, expanding its product competitiveness in the TNF-α inhibitor market. The company announced acquisition of the Phase 1 c...
Astellas’s ‘Vesicare’ filed lawsuit for infringement by CorePharm Bio
On the 4th, Astellas Korea(CEO Hae-do Jung) announced it jointly filed a patent infringement prohibition trial against CorePharm Bio with Astellas Korea to the Seoul Central District Court.
The trial is in regards t...
Green Cross’s ‘Rixubis’ enters domestic hemophilia B marketThe Green Cross and Baxalta alliance will target the hemophilia B market.
According to the industry concerned on the 9th, Green Cross will take in charge of domestic distribut...
|
Poorly-performed osteoporosis market
Bisphosphonate(BP) drugs, osteoporosis treatments that are known to have particular administration, have recorded poor performances.
On the other hand, SERM-type drugs have become the only drugs which showed potentia...
